TRENDING :  Market Movers  |  Top 50   SPY (0.23%)    TSLA (-2.49%)    CANF (1.36%)    BYND (-2.96%)    BTCUSD (%)    ONCS (-3.12%)    AMZN (0.43%)    TVIX (-4.25%)    VXX (-2.07%)    ROKU (6.45%)    ACAD (2.45%)    OIH (-1.43%)    MCHP (-1.44%)    MAXR (-13.79%)    IRBT (0.03%)    IP (-0.24%)    INTC (0.09%)    GDX (0.64%)    FTNT (0.33%)    ECOR (-4.53%)    DNR (3.23%)    DIS (0.05%)    DFRG (2.06%)    CMG (-0.69%)    BIOC (9.74%)

 RGLS - Regulus Therapeutics Inc.

$1.37 [0.05][3.79%]

Next Earnings

8/8/2019

AMC

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

2


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $1.50
Low $1.50
Average $1.50
Current $1.37

CompanyAnalyst NamePT ActionActionRatingTargetDate
Wells FargoJim BirchenoughLowersMaintainsBuy$1.5003/19/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $RGLS

No traders tracking are currently recommending this stock

TRENDING ARTICLES



Will Regulus (RGLS) Report Negative Q1 Earnings? What You Should Know

05/02/19
Wall Street expects a year over year increase in earnings on flat revenues when Regulus RGLS reports results for the quarter ended March 2019 While this widely known consensus outlook is important in gauging the company s earnings picture a powerful factor that could impact its near term